EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis

Daiki Tokuyasu, Shigeaki Suzuki iD, Akiyuki Uzawa iD, Yuriko Nagane, Masayuki Masuda, Shingo Konno, Tomoya Kubota, Makoto Samukawa, Takamichi Sugimoto, Kei Ishizuchi, Munenori Oyama, Manato Yasuda and 9 more

Annals of Clinical and Translational Neurology · 2024-05 · 11 (5) · 1338-1346

DOI: 10.1002/acn3.52051 ↗

At a glance

Journal article in Annals of Clinical and Translational Neurology, published online on 2024-04-04. Written by Daiki Tokuyasu and 20 co-authors. Institution: Department of Neurology, Keio University School of Medicine, Tokyo, Japan. Major MEDLINE topics: Myasthenia Gravis, Antibodies, Monoclonal, Humanized, Complement Inactivating Agents. Cited 28 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY 4.0). Funded by: JSPS KAKENHI.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

Eculizumab and ravulizumab are complement protein C5 inhibitors, showing efficacy and tolerability for patients with anti‐acetylcholine receptor‐positive (AChR+) generalized myasthenia gravis (gMG) in phase 3 clinical trials and subsequent analyses. The purpose of the present study was to evaluate the clinical significance of eculizumab and switching to ravulizumab for refractory AChR+ gMG patients in the real‐world experience.

Methods

Among the database of Japan MG registry survey 2021, we studied AChR+ gMG patients who received eculizumab. We also evaluated these patients who switched from eculizumab to ravulizumab. Responder was defined as an improvement of at least 3 points in MG‐ADL. We performed a questionnaire of preference between eculizumab and ravulizumab.

Results

Among 1,106 patients with AChR+ gMG, 36 patients (3%) received eculizumab (female 78%, mean age 56.0 years). Eculizumab was preferentially used in severe and refractory MG patients. The duration of eculizumab treatment was 35 months on average. MG‐ADL improved from 9.4 ± 4.9 to 5.9 ± 5.1, and 25 (70%) of the 36 gMG patients were responders. Postintervention status was markedly improved after the eculizumab treatment. Of 13 patients who did not continue eculizumab, 6 showed insufficiencies. Early onset MG was most effective. However, 15 patients switching from eculizumab to ravulizumab kept favorable response and tolerability. Questionnaire surveys showed preference for ravulizumab over eculizumab.

Interpretation

Eculizumab and switching to ravulizumab showed to be effective for refractory AChR+ gMG patients in clinical settings.

Subjects

MeSH terms (MEDLINE)

Myasthenia GravisAntibodies, Monoclonal, HumanizedComplement Inactivating AgentsHumansFemaleMaleMiddle AgedAgedAdultDrug SubstitutionRegistriesJapan

Substances

Antibodies, Monoclonal, HumanizedComplement Inactivating Agents

Authors and institutions

  • Department of Neurology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan.
  • Department of Neurology, Tokyo Medical University, Tokyo, Japan.
  • Department of Neurology, Toho University Ohashi Medical Center, Tokyo, Japan.
  • Department of Clinical Laboratory and Biomedical Sciences, Division of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan.

ORCID profiles: Shigeaki Suzuki, Akiyuki Uzawa

Funding

  • JSPS KAKENHI

Cite

APA

Tokuyasu, D., Suzuki, S., Uzawa, A., Nagane, Y., Masuda, M., Konno, S., Kubota, T., Samukawa, M., Sugimoto, T., Ishizuchi, K., Oyama, M., Yasuda, M., Akamine, H., Onishi, Y., Suzuki, Y., Kawaguchi, N., Minami, N., Kimura, T., Takahashi, M. P., …, & Utsugisawa, K. (2024). Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis. Annals of Clinical and Translational Neurology, 11(5), 1338-1346. https://doi.org/10.1002/acn3.52051

Vancouver

Tokuyasu D, Suzuki S, Uzawa A, Nagane Y, Masuda M, Konno S, et al. Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis. Annals of Clinical and Translational Neurology. 2024;11(5):1338-1346. doi:10.1002/acn3.52051

BibTeX
@article{Tokuyasu2024,
  author = {Tokuyasu, Daiki and Suzuki, Shigeaki and Uzawa, Akiyuki and Nagane, Yuriko and Masuda, Masayuki and Konno, Shingo and Kubota, Tomoya and Samukawa, Makoto and Sugimoto, Takamichi and Ishizuchi, Kei and Oyama, Munenori and Yasuda, Manato and Akamine, Hiroyuki and Onishi, Yosuke and Suzuki, Yasushi and Kawaguchi, Naoki and Minami, Naoya and Kimura, Takashi and Takahashi, Masanori P and Murai, Hiroyuki and Utsugisawa, Kimiaki},
  title = {Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2024},
  volume = {11},
  number = {5},
  pages = {1338--1346},
  doi = {10.1002/acn3.52051}
}
Start for free →